Epelsiban

Drug Profile

Epelsiban

Alternative Names: 557296; GSK557296

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Infertility; Premature ejaculation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Infertility(In volunteers) in USA (PO, Tablet)
  • 13 Jun 2016 GlaxoSmithKline terminates phase I trial in Infertility (In volunteers) in USA (IV) (NCT02213029)
  • 06 Jun 2016 GlaxoSmithKline plans a phase II trial in Adenomyosis in USA (NCT02794467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top